A Phase 1 interventional study of CTX-471 and Pembrolizumab (KEYTRUDA®) in Locally Advanced Solid Tumor, Metastatic Cancer and Non-small Cell Lung Cancer, sponsored by Compass Therapeutics. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Compass Therapeutics · Phase 1, Interventional, and Treatment
The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,056 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.
Among the 2,056 studies in Neoplasm Metastasis with a site in United States, this one is the 521st largest by enrollment of the 1,865 interventional ones that give a count, is one of 90 that started in 2019, is one of 710 in phase 1, and was the 1,320th registered.
4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.
Browse Neoplasm Metastasis studies →346 of the 2,056 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,056 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 978 · Phase 2 855 · Phase 3 186 · Phase 4 15
First in 1978; this study’s year is marked. 90 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 50 across 3,275 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 43 across the 1,865 interventional studies, 100 across the 139 observational. Of the 1,391 that completed or were terminated, 602 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
927 of 2,056 have an industry lead sponsor. The 10 most frequent:
Compass Therapeutics is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Compass Therapeutics has 1 study filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
203 of the studies in Neoplasm Metastasis with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03525873Phase 3M.D. Anderson Cancer CenterA Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy | 2026-12-31 |
| NCT03927885Phase 3M.D. Anderson Cancer CenterOpen Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | 2026-12-31 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 203 to your calendar (.ics) → With an account.
Among the 2,056 studies in Neoplasm Metastasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In each arm (monotherapy and combination therapy), data from Part 1 (dose escalation) and Part 2 (dose expansion) were combined by dose level for reporting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed diagnosis:
Adequate bone marrow function defined by of ≥ 1.5×10\^9/L, count of ≥100.0×10\^9/L, and of ≥ 9.0 g/dL (with or without transfusion)
a. For Combination Arm 2: these criteria must be met without packed red blood cell (pRBC) transfusion within the prior 2 weeks. Patients can be on a stable dose of erythropoietin (≥ approximately 3 months)
Exclusion Criteria:
Active virus (HBV), virus (HCV), or infection (HIV) or a positive serological test at Screening within 28 days of dosing with CTX 471
HIV infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of CTX-471 depending on cohort at enrollment
Drug: CTX-471
Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)
Drug: CTX-471
Escalating doses of CTX-471 in combination with pembrolizumab (KEYTRUDA® ) depending on cohort at enrollment
Drug: CTX-471 · Drug: Pembrolizumab (KEYTRUDA®)
Two cohorts of CTX-471 (0.3 mg/kg and 0.6 mg/kg) in combination with pembrolizumab (KEYTRUDA® ) (400 mg) in three tumor type subgroups. Cohort 1 - Group 1A - NSCLC , Group 1B -SCLC and Group 1C - Melanoma. Cohort 2 Group 2A - NSCLC, Group 2B - SCLC and Group 2C -Melanoma.
Drug: CTX-471 · Drug: Pembrolizumab (KEYTRUDA®)
IV infusion every 2 weeks
IV infusion every 6 weeks
Also known as: KEYTRUDA®
Number of Participants With Dose Limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), and/or Changes in Clinical Laboratory Abnormalities
Hematological and nonhematological DLTs were defined in the protocol. TEAE is an occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-471. Change in clinical laboratory abnormalities is defined as a TEAE related to laboratory results.
Time frame: From first CTX-471 dose to 4 weeks after first dose for DLTs in monotherapy arms, to 6 weeks after first dose for DLTs in combination arms, to 60 days after last dose for TEAEs and clinical laboratory abnormalities in both monotherapy and combination arms
Maximum Serum Concentration (Cmax) of CTX-471
Calculated from plasma concentrations measured from samples collected at times shown below
Time frame: Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
Area Under the Serum Concentrations of CTX-471 Versus Time Curve (AUC)
AUC(0-24) = AUC from time 0 to 24 hours (1 day); AUC(0-336) = AUC from time 0 to 336 hours (14 days). Calculated from plasma concentrations measured from samples collected at the time points below.
Time frame: Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
Half-life (t1/2) of Serum Concentration of CTX-471
Time frame: Calculated from plasma concentrations measured from samples collected before the first dose of CTX-471; 1, 6, and 24 hours after the first dose of CTX-471; and before the second dose of CTX-471 (Weeks 1 to 3)
Development of Anti-drug Antibodies
Frequency of patients with a negative test result for antibody to CTX-471 prior to treatment who had a positive test for antibody to CTX-471 after treatment. For monotherapy arms, end of treatment was an average 18 weeks, and 60 days after end of treatment was an average 27 weeks. For combination arms, end of treatment was an average 15 weeks, and 60 days after end of treatment was an average 24 weeks.
Time frame: Monotherapy arms: Weeks 3, 5, 9, 13, 17, 21, 25, 29, 33, and 37 and end of treatment and 60 days after end of treatment; Combination therapy arms: Weeks 5, 9, 13, 19, 25, 31, and 37 and end of treatment and 60 days after end of treatment
Overall Response Rate
Percentage of patients whose best overall response to treatment was complete response or partial response (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)
Time frame: From the first dose of CTX-471 to treatment discontinuation (average of 18 weeks for monotherapy groups and and average of 15 weeks for combination groups)
Duration of Response
Time period from date of CT or MRI that first confirmed complete or partial response to date of CT or MRI that first confirmed progression of disease (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)
Time frame: From first date of complete or partial response to first date of disease progression or death
Progression-free Survival
Time from the first dose of CTX-471 to disease progression (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1) or death
Time frame: From the first dose of CTX-471 to progression of disease or death
Overall Survival
Time from the first dose of CTX-471 to death
Time frame: From the first dose of CTX-471 to death
| Milestone | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Started | 3 | 33 | 36 | 7 | 3 | 9 | 9 |
| Completed | 0 | 5 | 3 | 2 | 0 | 0 | 0 |
| Not completed | 3 | 28 | 33 | 5 | 3 | 9 | 9 |
| Withdrew: Death | 3 | 22 | 30 | 5 | 2 | 5 | 5 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Study termination by sponsor | 0 | 1 | 0 | 0 | 1 | 2 | 2 |
| Withdrew: Clinical deterioration | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Hematological and nonhematological DLTs were defined in the protocol. TEAE is an occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-471. Change in clinical laboratory abnormalities is defined as a TEAE related to laboratory results.
| Participants | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Dose-limiting toxicity | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Treatment-emergent adverse event | 1 | 33 | 36 | 7 | 3 | 8 | 9 |
| Blood creatinine increased | 0 | 7 | 4 | 1 | 1 | 1 | 0 |
| Alanine aminotransferase increased | 0 | 3 | 3 | 2 | 0 | 0 | 0 |
| Aspartate aminotransferase increased | 0 | 2 | 5 | 1 | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | 0 | 4 | 3 | 0 | 0 | 0 | 0 |
| Lipase increased | 0 | 2 | 3 | 0 | 1 | 0 | 1 |
| Amylase increased | 0 | 1 | 3 | 0 | 1 | 0 | 0 |
| Platelet count decreased | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| International normalised ratio increased | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Transaminases increased | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin conjugated increased | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Blood lactate dehydrogenase increased | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood lactic acid increased | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood phosphorus decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Carbon dioxide decreased | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Troponin increased | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| White blood cell count decreased | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| White blood cell count increased | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hyponatraemia | 0 | 5 | 9 | 0 | 0 | 0 | 1 |
| Hyperkalaemia | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Hypomagnesaemia | 0 | 1 | 3 | 0 | 1 | 0 | 0 |
| Hypophosphataemia | 0 | 3 | 0 | 1 | 0 | 0 | 0 |
| Hypokalaemia | 0 | 2 | 1 | 0 | 1 | 0 | 2 |
| Hyperphosphataemia | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminaemia | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| Hypocalcaemia | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Hypercalcaemia | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Hyperglycaemia | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesaemia | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hypernatraemia | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Hypoglycaemia | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Anaemia | 1 | 9 | 12 | 3 | 1 | 2 | 1 |
| Neutropenia | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Calculated from plasma concentrations measured from samples collected at times shown below
| ng/mL | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Week 1 dose | 1564.5 ± 35.2 | 6308.4 ± 52.9 | 11249.9 ± 33.8 | 25403.4 ± 30.2 | NA ± NA | 7612.2 ± 4.2 | 7152.2 ± 286.3 |
| Week 9 dose (steady state) | 2950.0 ± NA | 9880.4 ± 34.9 | 10998.7 ± 17.6 | 25731.7 ± 38.1 | — | — | — |
AUC(0-24) = AUC from time 0 to 24 hours (1 day); AUC(0-336) = AUC from time 0 to 336 hours (14 days). Calculated from plasma concentrations measured from samples collected at the time points below.
| h∙ng/mL | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Week 1 AUC(0-24) | 33849.4 ± 38.4 | 123698.8 ± 50.5 | 208795.6 ± 38.7 | 498570.5 ± 32.5 | NA ± NA | 161090.8 ± 6.8 | 149520.7 ± 344.0 |
| Week 1 AUC(0-336) | 223886.8 ± 41.7 | 818109.9 ± 45.7 | 1579811.4 ± 27.5 | 3500751.4 ± 37.5 | NA ± NA | 1123811.4 ± 24.3 | 1034157.2 ± 357.5 |
| Week 9 (steady state) AUC(0-24) | 66000.0 ± NA | 184610.2 ± 21.9 | 224875.8 ± 16.7 | 466764.0 ± 55.4 | — | — | — |
| hours | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Half-life (t1/2) of Serum Concentration of CTX-471 | 147.9 ± 9.1 | 163.6 ± 27.8 | 159.2 ± 24.4 | 156.6 ± 19.9 | 126.9 ± 35.6 | 145.3 ± 30.5 | 167.8 ± 16.3 |
Frequency of patients with a negative test result for antibody to CTX-471 prior to treatment who had a positive test for antibody to CTX-471 after treatment. For monotherapy arms, end of treatment was an average 18 weeks, and 60 days after end of treatment was an average 27 weeks. For combination arms, end of treatment was an average 15 weeks, and 60 days after end of treatment was an average 24 weeks.
| Participants | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Week 3 | 0 | 0 | 1 | 1 | — | — | — |
| Week 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 9 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 13 | 2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 17 | 0 | 1 | 1 | 0 | — | — | — |
| Week 19 | — | — | — | — | 0 | 1 | 0 |
| Week 21 | 0 | 2 | 1 | 0 | — | — | — |
| Week 25 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Week 29 | 0 | 1 | 0 | 0 | — | — | — |
| Week 31 | — | — | — | — | 0 | 1 | 0 |
| Week 33 | 0 | 1 | 0 | 0 | — | — | — |
| Week 37 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| End of Treatment | 0 | 1 | 2 | 0 | 1 | 2 | 1 |
| 60 days after end of treatment | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
Percentage of patients whose best overall response to treatment was complete response or partial response (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)
| Participants | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Overall Response Rate | 0 | 4 | 1 | 0 | 0 | 0 | 0 |
Time period from date of CT or MRI that first confirmed complete or partial response to date of CT or MRI that first confirmed progression of disease (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)
| months | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Duration of Response | — | 24.43 (1.88 to 46.97) | 3.55 (3.55 to 3.55) | — | — | — | — |
Time from the first dose of CTX-471 to disease progression (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1) or death
| months | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Progression-free Survival | 3.55 (1.64 to 5.49) | 3.55 (0.95 to 42.07) | 3.52 (1.51 to 14.77) | 3.05 (1.74 to 4.21) | 1.84 (1.58 to 20.53) | 2.89 (1.64 to 14.77) | 2.36 (1.18 to 3.68) |
Time from the first dose of CTX-471 to death
| months | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| Overall Survival | 14.70 (9.57 to 14.90) | 14.64 (1.38 to 49.87) | 9.41 (0.72 to 28.32) | 11.05 (2.43 to 22.73) | 4.05 (3.55 to 26.78) | 8.65 (0.26 to 19.14) | 6.78 (2.07 to 21.48) |
Collected over From the signing of the informed consent form through 60 days after the last dose of CTX-471 (average of 27 weeks) for the monotherapy arms, from the signing of the informed consent form through 90 days after the last dose of pembrolizumab (average of 28 weeks) for the combination arms. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CTX-471 Monotherapy 0.1 mg/kg | 3/3 (100%) | 1/3 (33.3%) | 2/3 (66.7%) |
| CTX-471 Monotherapy 0.3 mg/kg | 22/33 (66.7%) | 11/33 (33.3%) | 33/33 (100%) |
| CTX-471 Monotherapy 0.6 mg/kg | 30/36 (83.3%) | 17/36 (47.2%) | 36/36 (100%) |
| CTX-471 Monotherapy 1.2 mg/kg | 5/7 (71.4%) | 3/7 (42.9%) | 7/7 (100%) |
| CTX-471 Combination 0.1 mg/kg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| CTX-471 Combination 0.3 mg/kg | 5/9 (55.6%) | 2/9 (22.2%) | 8/9 (88.9%) |
| CTX-471 Combination 0.6 mg/kg | 5/9 (55.6%) | 4/9 (44.4%) | 9/9 (100%) |
| Event | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/3 | 1/33 | 1/36 | 0/7 | 0/3 | 0/9 | 0/9 |
| Urinary tract infectionInfections and infestations | 0/3 | 1/33 | 0/36 | 0/7 | 1/3 | 0/9 | 0/9 |
| Bile duct obstructionHepatobiliary disorders | 0/3 | 0/33 | 0/36 | 0/7 | 1/3 | 0/9 | 0/9 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 0/33 | 0/36 | 0/7 | 1/3 | 0/9 | 0/9 |
| Tubulointerstitial nephritisRenal and urinary disorders | 0/3 | 0/33 | 0/36 | 0/7 | 1/3 | 0/9 | 0/9 |
| HeadacheNervous system disorders | 0/3 | 0/33 | 0/36 | 1/7 | 0/3 | 0/9 | 0/9 |
| Pericardial effusionCardiac disorders | 0/3 | 0/33 | 0/36 | 1/7 | 0/3 | 0/9 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/33 | 0/36 | 1/7 | 0/3 | 0/9 | 0/9 |
| Platelet count decreasedInvestigations | 0/3 | 0/33 | 1/36 | 1/7 | 0/3 | 0/9 | 0/9 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 0/3 | 0/33 | 0/36 | 1/7 | 0/3 | 0/9 | 0/9 |
| Event | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/3 | 13/33 | 12/36 | 2/7 | 3/3 | 6/9 | 4/9 |
| PyrexiaGeneral disorders | 1/3 | 4/33 | 5/36 | 2/7 | 2/3 | 2/9 | 0/9 |
| PainGeneral disorders | 0/3 | 2/33 | 2/36 | 0/7 | 2/3 | 0/9 | 0/9 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 6/33 | 6/36 | 0/7 | 2/3 | 5/9 | 3/9 |
| NauseaGastrointestinal disorders | 1/3 | 9/33 | 10/36 | 2/7 | 2/3 | 2/9 | 1/9 |
| VomitingGastrointestinal disorders | 1/3 | 9/33 | 9/36 | 0/7 | 2/3 | 1/9 | 1/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 5/33 | 5/36 | 1/7 | 2/3 | 2/9 | 2/9 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 2/33 | 2/36 | 0/7 | 2/3 | 2/9 | 1/9 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/3 | 7/33 | 5/36 | 1/7 | 2/3 | 1/9 | 1/9 |
| HypertensionVascular disorders | 0/3 | 3/33 | 4/36 | 0/7 | 2/3 | 3/9 | 0/9 |
| Age, Categorical(Participants) | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 12 | 12 | 4 | 1 | 6 | 2 | 38 |
| >=65 years | 2 | 21 | 24 | 3 | 2 | 3 | 7 | 62 |
| Sex: Female, Male(Participants) | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 12 | 14 | 1 | 2 | 5 | 3 | 38 |
| Male | 2 | 21 | 22 | 6 | 1 | 4 | 6 | 62 |
| Ethnicity (NIH/OMB)(Participants) | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 4 |
| Not Hispanic or Latino | 3 | 31 | 34 | 6 | 3 | 9 | 9 | 95 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 | 2 | 0 | 0 | 0 | 8 |
| White | 2 | 30 | 30 | 5 | 3 | 9 | 9 | 88 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | CTX-471 Monotherapy 0.1 mg/kg | CTX-471 Monotherapy 0.3 mg/kg | CTX-471 Monotherapy 0.6 mg/kg | CTX-471 Monotherapy 1.2 mg/kg | CTX-471 Combination 0.1 mg/kg | CTX-471 Combination 0.3 mg/kg | CTX-471 Combination 0.6 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 3 | 33 | 36 | 7 | 3 | 9 | 9 | 100 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2019 to primary completion in May 2025, 72 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.
The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Compass Therapeutics